Literature DB >> 15024588

[Cardiopulmonary exercise capacity increases after interventional ASD-closure].

M Weber1, T Neumann, M Rau, R Brandt, T Dill, C Maikowski, V Mitrovic, C Hamm.   

Abstract

BACKGROUND: In patients with atrial septal defects of the secundum-type (ASD), exercise tolerance is reduced. Generally, ASD closure is recommended in symptomatic patients and in patients with a relevant left-to-right shunt (Qp/Qs > 1.5). Only few data are available concerning objective parameters of cardiopulmonary exercise capacity. The aim of this study was to evaluate exercise capacity as achieved by ergospirometry in adult patients with an ASD at baseline and in the long-term following transcatheter closure. METHODS AND
RESULTS: Thirty consecutive patients (8 male; mean age 43.4 years; defect size 23.5 mm; pulmonary-to-systemic flow ratio (Qp/Qs) 1.94) performed exercise testing on a supine bicycle ergometer. At baseline, oxygen consumption at maximal exercise (VO(2) peak) was 14.3 ml/min kg, oxygen consumption at the anaerobic threshold (VO(2)-AT) was 11.2 ml/min/kg and maximal achieved workload was 86 Watt. At one and six months after ASD-closure, there was no relevant increase of the VO(2) peak, the VO(2)-AT or the maximal workload. After 12 months, there was a significant increase of the VO(2) peak (15.1 ml/min/kg, p = 0.049), the VO(2)-AT (13 ml/min/kg, p < 0.001) and the maximal workload (99 Watt, p < 0.01). An increase of the oxygen consumption at the anaerobic threshold (Delta VO(2) AT) could be seen in 24 out of 30 patients and was independent of shunt volume (Q(p)/Q(s) < or = 2, 1.95 ml/ min/kg; Q(p)/Q(s) > 2, 2.13 ml/min/ kg; ns), defect size (defect < or = 24 mm, 2.0 ml/min/kg; defect > 24 mm, 1.5 ml/min/kg; ns), age (age < or = 44 years, 1.97 ml/min/kg; age >44 years, 1.66 ml/min/kg; ns), gender (female 1.56 ml/min/ kg; male 1.91 ml/min/kg; ns) and of the existence of a residual shunt. Highly symptomatic patients had a tendency to have greater benefit from ASD-closure as compared to mildly symptomatic patients (NYHA 0/I 1.85 ml/min/kg; NYHA II 1.5 ml/min/ kg; NYHA III 2.7 ml/min/kg; ns). There was no correlation between shunt volume, shunt size, pulmonal arterial pressure and increase of the oxygen consumption at the anaerobic threshold (Delta VO(2) AT).
CONCLUSION: There is no relevant improvement in exercise capacity early (1-6 months) after interventional ASD-closure, but late after ASD-closure (12 months) exercise capacity improves significantly. This improvement can be found in almost all patients independent of gender, age, symptoms, shunt volume and defect size.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024588     DOI: 10.1007/s00392-004-0042-z

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  4 in total

1.  Left ventricular adaptation after atrial septal defect closure assessed by increased concentrations of N-terminal pro-brain natriuretic peptide and cardiac magnetic resonance imaging in adult patients.

Authors:  M Weber; T Dill; A Deetjen; T Neumann; O Ekinci; J Hansel; A Elsaesser; V Mitrovic; C Hamm
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

2.  Noninvasive cardiac output measurement at rest and during exercise in pediatric patients after interventional or surgical atrial septal defect closure.

Authors:  Gesa Wiegand; Wolfhard Binder; Heidi Ulmer; Renate Kaulitz; Joachim Riethmueller; Michael Hofbeck
Journal:  Pediatr Cardiol       Date:  2012-02-22       Impact factor: 1.655

3.  Changes in Strain Pattern and Exercise Capacity after Transcatheter Closure of Atrial Septal Defects.

Authors:  Jung Yoon Kim; Bong-Sic Yun; Sunho Lee; Se Yong Jung; Jae Young Choi; Nam Kyun Kim
Journal:  Korean Circ J       Date:  2017-03-14       Impact factor: 3.243

4.  Latent pulmonary hypertension in atrial septal defect: Dynamic stress echocardiography reveals unapparent pulmonary hypertension and confirms rapid normalisation after ASD closure.

Authors:  S A Lange; M U Braun; S P Schoen; R H Strasser
Journal:  Neth Heart J       Date:  2013-07       Impact factor: 2.380

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.